NeurologyLive® Mind Moments®

De: NeurologyLive
Escúchala gratis

  • Resumen

  • Mind Moments®, a podcast from NeurologyLive® (https://www.neurologylive.com/) , brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/) .
    Más Menos
Episodios
  • 115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis

    115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis
    Jul 31 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Michael Weiss, chief executive officer of TG Therapeutics, discussed ublituximab (Briumvi), a recently approved anti-CD20 therapy for relapsing multiple sclerosis, and the advantages it brings to patients. Specifically, he talked about the Department of Veteran Affairs' decision to award national contract to ublituximab as the preferred anti-CD20 for this patient population, and how this facilitates greater access to the treatment. In addition, he discussed how the knowledge profile of the agent has grown over time, as well as the additional efforts to gain a better understanding of its efficacy and safety. Furthermore, he spoke on the differences between ublituximab and other approved agents, and why it may be more applicable to certain patients.

    Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page.

    Episode Breakdown:
    • 1:05 – Significance of ublituximab awarded national contract as preferred anti-CD20 for relapsing MS
    • 3:30 – Advantages and differences of ublituximab vs approved therapies for MS
    • 11:40 – Neurology News Minute
    • 14:30 – Growing knowledge profile of ublituximab over the years
    • 19:05 – Future plans of ubtlituximab; long-term goals of the therapy

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Eli Lilly Announces Date for Donanemab FDA AdComm Hearing
    • Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne
    • ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    26 m
  • 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

    120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve
    Jul 26 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Douglas Wajda, PhD, an assistant professor of neurology at Cleveland State University, discussed a pilot study presented at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting using a functional electrical stimulation approach, Neural Sleeve, to treat gait in MS. Wajda, who has been studying gait in MS for several years, gave clinical insight on the functionality and feasibility of this approach, and the personalized treatment patients can gain from it. He also discussed the pilot study in detail, including the major end points and takeaways from the small group of patients observed.


    Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.

    Episode Breakdown:
    • 1:00 – Functionality of Neural Sleeve
    • 2:45 – Feasibility and self-administration of Neural Sleeve
    • 3:50 – Neurology News Minute
    • 5:50 – Greatest clinical takeaways from pilot study
    • 8:15 – Steps in advancing this therapeutic approach
    • 9:45 – Challenges with gait in MS and personalizing treatment methods

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Gene Therapy LX2006 Positively Impacts Cardiac Biomarkers of Friedreich Ataxia, Clinical Data Show
    • Buntanetap Transitioning to Crystal Form Following FDA Go-Ahead
    • Endo Voluntarily Recalls One Lot of Clonazepam Tablets Following Mislabeling Error

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    14 m
  • 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease

    119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
    Jul 12 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease (PD). She gave an overview of how the test is utilized in clinic, ways to interpret results, and the right personnel needed to ensure an accurate diagnosis. In addition, she provided clarity on the role of alpha-synuclein in PD, the advances in research in this area, and how the test incorporates this prominent biomarker. Furthermore, Husain-Wilson detailed some of the next steps in further optimizing the test in clinical settings, highlighting the importance of other non-movement disorder specialists who will play a major role in the diagnostic evaluation of future patients with PD.


    Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page.

    Episode Breakdown:
    • 1:10 – Step by step process on how Syn-One test is used; considerations after process is done
    • 3:15 – How the test differentiates PD from other neurodegenerative disorders
    • 9:50 – Neurology News Minute
    • 12:20 – Value and role in assessing alpha-synuclein in PD
    • 14:50 – Ways to further optimize Syn-One going forward

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease
    • Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study
    • Gene Therapy AMT-130 Slows Huntington Disease Progression in Interim Phase 1/2 Trials

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    20 m
Enfermedades Físicas Hygiene & Healthy Living Ciencia
Más Menos

Lo que los oyentes dicen sobre NeurologyLive® Mind Moments®

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles